AbbVie (NYSE:ABBV) Shares Up 2.6% – What’s Next?

AbbVie Inc. (NYSE:ABBV) rose 2.6% on Wednesday . The stock traded as high as $266.97 and last traded at $265.63. Approximately 5,440,532 shares traded hands during trading, a decline of 21% from the average session volume of 6,880,757 shares. The stock had previously closed at $258.92.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Acquisition financing completed: AbbVie completed a multitr tranche offering of senior notes, reported at approximately $9 billion to $10 billion, to support its planned acquisition of Apogee Therapeutics. The deal is intended to expand AbbVie’s pipeline, particularly in immunology, and may help diversify growth as Humira-related pressures continue. AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition
• Neutral Sentiment: Immunology scholarship announced: AbbVie named 34 recipients of its 2026 Immunology Scholarship, marking the program’s 10th year. The announcement reinforces the company’s patient-support efforts but is unlikely to materially affect near-term earnings or valuation. AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients
• Neutral Sentiment: Positive operating backdrop: AbbVie’s latest reported quarter exceeded analyst expectations, with revenue up 10.2% year over year and quarterly guidance calling for EPS of $3.84 to $3.88. These results provide support for investor confidence, though they were not new announcements in the latest news cycle.
• Negative Sentiment: Executive stock sale: EVP and Chief Business/Strategy Officer Nicholas Donoghoe sold 32,710 AbbVie shares for approximately $8.18 million, reducing his position by about 30.5%. Insider sales can weigh modestly on sentiment, although the transaction alone does not establish a change in the company’s outlook. Nicholas Donoghoe Insider Trading Information

Wall Street Analyst Weigh In

ABBV has been the subject of a number of recent analyst reports. Citigroup upped their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. BMO Capital Markets boosted their target price on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Weiss Ratings upgraded shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. HSBC restated a “buy” rating and set a $300.00 target price on shares of AbbVie in a research note on Monday, July 6th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $296.00 target price on shares of AbbVie in a research note on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $275.73.

AbbVie Stock Up 2.6%

The business has a 50-day moving average price of $246.17 and a 200-day moving average price of $226.63. The firm has a market capitalization of $469.31 billion, a P/E ratio of 75.04, a PEG ratio of 0.83 and a beta of 0.30.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. AbbVie’s dividend payout ratio is presently 195.48%.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. ACT Advisors LLC. boosted its stake in shares of AbbVie by 2.5% in the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock valued at $425,000 after purchasing an additional 41 shares in the last quarter. Willner & Heller LLC grew its holdings in shares of AbbVie by 0.7% during the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock valued at $1,472,000 after purchasing an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC increased its position in AbbVie by 3.1% during the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after purchasing an additional 43 shares in the last quarter. Fielder Capital Group LLC increased its position in AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock worth $637,000 after purchasing an additional 43 shares in the last quarter. Finally, Bank of Jackson Hole Trust lifted its stake in AbbVie by 0.6% in the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after purchasing an additional 44 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.